Apellis Pharmaceuticals Inc (APLS)
47.49
+1.44
(+3.13%)
USD |
NASDAQ |
May 02, 16:00
46.72
-0.77
(-1.62%)
Pre-Market: 08:39
Apellis Pharmaceuticals Debt to Equity Ratio: 0.4783 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.4783 |
| September 30, 2023 | 0.4002 |
| June 30, 2023 | 0.2689 |
| March 31, 2023 | 0.2252 |
| December 31, 2022 | 0.5459 |
| September 30, 2022 | 0.3014 |
| June 30, 2022 | 0.5661 |
| Date | Value |
|---|---|
| March 31, 2022 | 0.4092 |
| December 31, 2021 | 0.9515 |
| September 30, 2021 | -3.308 |
| June 30, 2021 | -2.731 |
| March 31, 2021 | 7.475 |
| December 31, 2020 | 1.754 |
| September 30, 2020 | 3.342 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-3.308
Minimum
Sep 2021
7.475
Maximum
Mar 2021
0.7628
Average
0.4437
Median
Debt to Equity Ratio Benchmarks
| Sarepta Therapeutics Inc | 1.289 |
| Blueprint Medicines Corp | 1.828 |
| Alnylam Pharmaceuticals Inc | -4.626 |
| Ionis Pharmaceuticals Inc | 3.317 |
| Madrigal Pharmaceuticals Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 788.73M |
| Total Liabilities (Quarterly) | 594.21M |
| Shareholders Equity (Quarterly) | 194.52M |
| Current Ratio | 3.095 |
| Net Debt Paydown Yield | -0.00% |